New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
06:21 EDTREGNRegeneron shares attractive at current levels, says Citigroup
Citigroup expects sales of Eylea to rebound in Q2 and it finds shares of Regeneron attractive at current levels. Citi says the stock has been weak over the past two weeks amid concerns that use of Avastin will grow. After surveying 31 retinal specialists, Citi keeps a Buy rating on Regeneron with a $390 price target.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
06:43 EDTREGNRegeneron price target raised to $527 from $445 at Leerink
Subscribe for More Information
April 20, 2015
09:20 EDTREGNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use